A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
NCT03895372
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
179
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
PF-06826647 or Placebo
DRUG:
PF-06826647
Sponsor
Pfizer